Cipla plans phased launch of Cinacalcet Hydrochloride

Cipla and its subsidiary Cipla USA, Inc., have launched a phase of generic Cinacalcet hydrochloride tablets in the US market.


The launch at this stage is a subject of ongoing litigation. Cinacalcet hydrochloride tablets 30mg, 60mg and 90mg is AB-rated generic therapeutic equivalent version of Sensipar, marketed by Amgen, Inc.



Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis. It is also useful for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma. Lastly, it is beneficial for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.



The shares of Cipla on Wednesday opened at Rs. 551.40 against Tuesday’s close of Rs. 548.55 per share. At 14:42 hours, the shares were trading at Rs. 545.85, down by 0.49 per cent. The stock reached an intraday high of Rs. 551.40 and an intraday low of Rs. 542.75 per share on the BSE. The 52-week high stood at Rs. 678 and the 52-week low was Rs 483.75 per share on the BSE.



Meanwhile, Sensex was quoting 36,614.40 level, up by 0.47 per cent or 171.86 points